Mesna Baxter Healthcare

Mesna, the active ingredient in Mesna Baxter Healthcare, is a uroprotective agent presented as an injection solution for intravenous use. It protects the bladder urothelium by preventing hemorrhagic cystitis in adult patients receiving cyclophosphamide or ifosfamide chemotherapy.

GNH USA supplies Mesna Baxter Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics, and research institutions worldwide across multiple regions.

Mesna is employed as a uroprotective adjunct in chemotherapy protocols that generate the toxic metabolite acrolein. - Cyclophosphamide therapy: prevents hemorrhagic cystitis during treatment. - Ifosfamide therapy: reduces bladder toxicity risk in patients receiving the drug. - High‑dose chemotherapy regimens: provides bladder protection when intensive protocols include cyclophosphamide or ifosfamide.

Mesna may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea - Vomiting - Headache - Injection‑site discomfort

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension or shock - Pulmonary edema - Acute renal failure

When using Mesna, several precautions should be observed to ensure safety and efficacy. - Assess renal function: evaluate baseline creatinine clearance before initiation. - Ensure adequate hydration: maintain high fluid intake to promote urinary excretion of the drug. - Monitor for bladder irritation: watch for dysuria or hematuria during therapy. - Observe for hypersensitivity: discontinue if signs of rash, itching or anaphylaxis appear. - Adjust dose in renal impairment: modify regimen according to renal function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mesna can interact with other medicines, affecting renal handling or hemodynamic stability.

Major Interactions (Avoid): - Concurrent nephrotoxic agents (e.g., aminoglycosides): increased risk of renal injury. - High‑dose cyclophosphamide without dose adjustment of Mesna: may reduce protective effect.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance fluid loss and affect hydration status. - NSAIDs: can diminish renal clearance of Mesna. - ACE inhibitors or ARBs: may potentiate hypotensive effects. - Anticoagulants: may increase risk of bleeding at injection sites.